Blog
GLP-1 News & Updates
FDA updates, drug pricing news, insurance coverage changes, and the latest clinical trial results for GLP-1 weight loss medications.
FDA Requests Safety Studies for Foundayo Despite Recent Approval
Just days after approving Foundayo, the FDA is asking Eli Lilly for additional data on potential heart, liver, and thyroid cancer risks.
The DoseLilly Responds to FDA Safety Request with Foundayo Heart Trial Data
Eli Lilly released cardiovascular safety data for Foundayo just days after FDA demanded additional studies on potential heart and liver risks.
The DoseFoundayo Hits Pharmacies as FDA Demands Additional Safety Data From Eli Lilly
Eli Lilly's new oral GLP-1 pill Foundayo launched in US pharmacies this week, but the FDA is requiring new safety studies for cardiovascular risks and other concerns.
The DoseWhy 1 in 10 People May Be Genetically Resistant to GLP-1 Drugs Like Ozempic
New Stanford research reveals specific genetic variants in 10% of people cause 'GLP-1 resistance,' explaining why Ozempic and Wegovy work poorly for some users despite having higher hormone levels.
The DoseLandmark Study Reveals GLP-1 Drugs' Surprising Health Benefits Beyond Weight Loss
A massive new analysis of 123 studies finds GLP-1 medications reduce risks for heart disease, kidney problems, cognitive decline, and fractures—reshaping how doctors think about these drugs.
The DoseRetatrutide Delivers Record 2% A1C Drop and 16.8% Weight Loss in Diabetes Trial
Eli Lilly's triple-agonist retatrutide achieved up to 2% A1C reduction and 36.6 pounds of weight loss in its first Phase 3 diabetes trial, marking a potential new standard for type 2 diabetes treatment.
The DoseSemaglutide Patent Expires in India, Triggering Generic GLP-1 Price War
Novo Nordisk's semaglutide patent expired in India on March 20, unleashing a wave of generic versions that cost 77% less than branded Ozempic and reshaping global GLP-1 access.
The DoseMedicare Launches Historic GLP-1 Coverage Bridge in July 2026
Medicare's new GLP-1 Bridge starts July 2026, offering Wegovy and Zepbound for $50/month to eligible beneficiaries with obesity and comorbidities.
The DoseGenetics May Predict Your GLP-1 Drug Response, Landmark Study Shows
New 23andMe research identifies genetic variants that explain why some people lose 20% of their weight on GLP-1s while others see minimal results.
The DoseMedicare Expands GLP-1 Coverage to 3.4 Million Seniors Under New CMS Rule
New Medicare rule reinterprets GLP-1 coverage criteria, enabling 3.4 million beneficiaries to access weight loss medications through cardiovascular risk reduction pathway.
The DoseAI-Powered GLP-1 Telehealth Giant MEDVi Faces FDA Warnings and Lawsuits
MEDVi, profiled by NYT as an AI-powered $1.8B telehealth success story, faces FDA warnings, RICO lawsuits over compounded GLP-1s, and major data breach affecting 1.6M patients.
The DoseFDA Safety Data Reveals Distinct Risk Profiles Across Different GLP-1 Drugs
New analysis of 137,000 FDA adverse event reports shows each GLP-1 medication has unique safety patterns, with semaglutide linked to more psychiatric events and concerning findings for women.